secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cerevel Therapeutics Holdings, Inc. (—)
CIK:        0001805387
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001193125-24-190764
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie completes $45/share acquisition of Cerevel; Cerevel becomes wholly owned subsidiary
--------------------------------------------------------------------------------

- Cerevel stockholders received $45.00 per share in cash for each share; total consideration not disclosed.
- All 12 board members resigned; Scott Reents (from Merger Sub) becomes sole director.
- Cerevel shares ceased trading on Nasdaq effective August 1, 2024; deregistration to follow.
- AbbVie reaffirms FY2024 adjusted EPS guidance of $10.71-$10.91, including $0.19 dilutive impact from deal.
- Key assets: emraclidine (schizophrenia, Phase 2 registration-enabling), tavapadon (Parkinson's, Phase 3 met primary endpoint).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/0001193125-24-190764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1805387/000119312524190764/d814318d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-190764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer